Monte Rosa Therapeutics Inc (GLUE) Stock Forecast & Price Target
Monte Rosa Therapeutics Inc · NASDAQ
$22.57-0.21 (-0.92%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Monte Rosa Therapeutics Inc, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $29.00 to $37.00, so the covering firms are broadly aligned. The average target of $33.00 sits 46% above the current $22.57. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 3 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.38 next quarter toward $-1.81 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Moderate Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Monte Rosa Therapeutics Inc.
As of Jul, 4 of 4 firms rate GLUE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
GLUE EPS & revenue forecast
EPS · NEXT QUARTER
$-0.38
Range $-0.60 – $0.11 · 7 analysts · +15% YoY
Next period, 7 analysts expect Monte Rosa Therapeutics Inc to earn $-0.38 a share (range $-0.60 – $0.11), versus $-0.33 a year earlier. Full-year consensus is $-1.59, growing to $-1.81 the year after.
REVENUE · NEXT QUARTER
$14.3M
Range $0 – $67.0M · 7 analysts · +12% YoY
Revenue is expected to reach $14.3M (range $0 – $67.0M), +12.0% year-over-year. Full-year consensus is $44.5M, rising to $58.2M next year.
Top analysts covering Monte Rosa Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on GLUE.
#1
Michael Schmidt
Guggenheim · Rank #1
Buy
$35.00+55.1% to target
Overall win rate
55%
+ Follow
#2
Edward Tenthoff
Piper Sandler · Rank #277
Buy
$37.00+63.9% to target
Overall win rate
29%
+ Follow
#3
Robert Driscoll
Wedbush · Rank #313
Buy
$17.00-24.7% to target
Overall win rate
30%
+ Follow
#4
Derek Archila
Wells Fargo · Rank #350
Buy
$29.00+28.5% to target
Overall win rate
32%
+ Follow
#5
MF
Marc Frahm
TD Cowen
Buy
No targeton GLUE
Coverage
—
+ Follow
GLUE stock forecast FAQ
What is GLUE's average 12-month price target?+
The 4 analysts with a live target average $33.00 for Monte Rosa Therapeutics Inc over the next 12 months, ranging from a $37.00 high to a $29.00 low.
Is GLUE stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for GLUE?+
The Street-high target is $37.00 (Piper Sandler), and the Street-low is $29.00 (Wells Fargo). The average of all 4 active targets is $33.00.
How many Wall Street analysts cover GLUE?+
4 analysts have an active rating on Monte Rosa Therapeutics Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering GLUE?+
Among analysts who currently cover GLUE, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #1). Their current call is Buy with a $35.00 target.
What is Monte Rosa Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.38 per share (range $-0.60 – $0.11) across 7 analysts. Full-year EPS is projected at $-1.59, rising to $-1.81 the following year.
How much revenue is Monte Rosa Therapeutics Inc expected to report next quarter?+
Consensus revenue is $14.3M (range $0 – $67.0M). Full-year revenue is projected at $44.5M, growing to $58.2M next year.
Have analysts been upgrading or downgrading GLUE lately?+
As of Jul, 4 of 4 firms rate GLUE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their GLUE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
